Wolfe Research on Eli Lilly (LLY): ph3 retratrutide results point to potential 'best-in-class' weight loss
Tweet Send to a Friend
Wolfe Research analyst Alexandria Hammond reiterated an Outperform rating and $1,325.00 price target on Eli Lilly (NYSE: LLY)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
